“Multinational Pharmaceutical Firms Enter China's Vaccine Market”

Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Immunization Newsbriefs (c) Copyright Information Inc., Bethesda, MD. Brought to you by the National Network for Immunization Information (NNii). Visit NNii's new website at http://www.immunizationinfo.org.

China's infant vaccine market has significant potential and, coupled with the research efforts made by the Chinese government to prevent and treat severe acute respiratory syndrome (SARS), multinational pharmaceutical companies are finding the market especially attractive. China has said it will allocate approximately 1.2 billion yuan ($144 million) to establish disease prevention and treatment centers and improve disease prevention systems, and up to 2 billion yuan has been set aside for SARS treatment and prevention. Wang Huoxiang, secretary general of the Chinese Preventative Medical Association, forecasts that the country's vaccine market will grow about 15 percent annually, compared to a worldwide level of growth of about 10 percent annually. Aventis of France, MSD Pharmaceutical, and GlaxoSmithKline currently make up more than 50 percent of the Chinese vaccine market.

Return to Vaccination News Home Page

DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.